YORVIPATH Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Yorvipath, and what generic alternatives are available?
Yorvipath is a drug marketed by Ascendis Pharma Bone and is included in one NDA. There are six patents protecting this drug.
This drug has ninety-eight patent family members in twenty-seven countries.
The generic ingredient in YORVIPATH is palopegteriparatide. One supplier is listed for this compound. Additional details are available on the palopegteriparatide profile page.
DrugPatentWatch® Generic Entry Outlook for Yorvipath
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 9, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for YORVIPATH?
- What are the global sales for YORVIPATH?
- What is Average Wholesale Price for YORVIPATH?
Summary for YORVIPATH
International Patents: | 98 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
DailyMed Link: | YORVIPATH at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for YORVIPATH
Generic Entry Date for YORVIPATH*:
Constraining patent/regulatory exclusivity:
TREATMENT OF HYPOPARATHYROIDISM IN ADULTS NDA:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for YORVIPATH
Drug Class | Parathyroid Hormone Analog |
US Patents and Regulatory Information for YORVIPATH
YORVIPATH is protected by six US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of YORVIPATH is ⤷ Sign Up.
This potential generic entry date is based on TREATMENT OF HYPOPARATHYROIDISM IN ADULTS.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting YORVIPATH
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
FDA Regulatory Exclusivity protecting YORVIPATH
TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
Exclusivity Expiration: ⤷ Sign Up
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
International Patents for YORVIPATH
See the table below for patents covering YORVIPATH around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2237799 | PROMÉDICAMENT COMPRENANT UN LINKER AUTO-CLIVABLE (PRODRUG COMPRISING A SELF-CLEAVABLE LINKER) | ⤷ Sign Up |
Israel | 207150 | מטרים תרופה המכיל תצמיד קושר@תרופה (Prodrug comprising a drug linker conjugate) | ⤷ Sign Up |
European Patent Office | 3518961 | COMPOSÉS DE PTH AYANT UN FAIBLE RAPPORT ENTRE LE PIC ET LE NIVEAU MINIMUM (PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS) | ⤷ Sign Up |
Japan | 7197468 | ⤷ Sign Up | |
Portugal | 2237799 | ⤷ Sign Up | |
Croatia | P20191052 | ⤷ Sign Up | |
New Zealand | 751969 | Dosage regimen for a controlled-release pth compound | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |